Eli Lilly and Co. last week said it is planning a head-to-head trial for its once-monthly injectable migraine drug Emgality against Biohaven Pharmaceuticals’ Nurtec ODT, an oral therapy taken every other day. Lilly is aiming for a 50% reduction in the number of headache days trial patients experience per month. Nurtec ODT is the only drug that is FDA-approved for both immediate migraine treatment and migraine prevention, and holds covered or better status under the pharmacy benefit for 78% of all insured lives. It is not covered for 18.4% of lives. Meanwhile, Emgality is 92% covered or better for migraine prevention.
SOURCE: MMIT Analytics, as of 6/17/21